Neurovalens Secures £6m Investment Led by the Investment Fund for Northern Ireland

Neurovalens, a global leader in non-invasive neuro-technology, has announced the successful closure of a £6m investment round, led by the Investment Fund for Northern Ireland (IFNI).

Based in Belfast, Neurovalens is a pioneering medical device company which specialises in leveraging the power of neuroscience and advanced technology to address a variety of global health challenges including insomnia, anxiety and post-traumatic stress disorder (PTSD).

Neurovalens has obtained medical device clearance from the US Food & Drug Administration (FDA) for two innovative products: the Modius Sleep device for treating insomnia and the Modius Calm device for managing anxiety.

The £6m funding round includes investment from new and existing investors. Led by a £1.5m investment by IFNI managed by Clarendon Fund Managers, the round includes £780,000 investment from Whiterock's Growth Capital Fund and strong follow-on support from existing investors.

Dr Jason McKeown, CEO of Neurovalens: "We're delighted to have the support of the Investment Fund for Northern Ireland and our other new and existing investors at this key stage in our journey."

To date, Neurovalens has raised approximately £20m in equity and debt funding from UK investors.